Collectively, our findings demonstrate that increased expression of Evi1 in vivo leads to the development of MDS/MPN–like disease, recapitulating the characteristic features observed in MDS/MPN patients with high EVI1 expression. Here, RUNX1 is linked to myeloproliferative disorder.